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© 2009 The Japan Society of Histochemistry and Cytochemistry In mammalian circadian rhythms, the transcriptional-translational feedback loop (TTFL)
consisting of a set of clock genes is believed to elicit the circadian clock oscillation. The
TTFL model explains that the accumulation and degradation of mPER and mCRY proteins
control the period-length (tau) of the circadian clock. Although recent studies revealed that
the Casein Kinase Iεδ (CKIεδ) regurates the phosphorylation of mPER proteins and the
circadian period-length, other kinases are also likely to contribute the phosphorylation of
mPER. Here, we performed small scale screening using 84 chemical compounds known
as kinase inhibitors to identify candidates possibly affecting the circadian period-length in
mammalian cells. Screening by this high-throughput real-time bioluminescence monitoring
system revealed that the several chemical compounds apparently lengthened the cellular
circadian clock oscillation. These compounds are known as inhibitors against kinases such
as Casein Kinase II (CKII), PI3-kinase (PI3K) and c-Jun N-terminal Kinase (JNK) in addition
to CKIεδ. Although these kinase inhibitors may have some non-specific effects on other
factors, our mini screening identified new candidates contributing to period-length control in
mammalian cells.
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I. Introduction
The mammalian circadian clock system generates daily
fluctuations in the several gene expressions to regulate many
aspects of near-24-hour rhythmicity such as behavior, phys-
iology, and metabolic processes, thereby allowing mammals
to anticipate the momentum of the day [4, 7, 12].
The molecular oscillation of circadian clock consists of
an interlocked positive and negative transcription/translation
feedback loop (TTFL) involving a set of clock genes and
clock-controlled output genes that link the oscillator to
clock-controlled processes [14]. CLOCK and BMAL1 are
basic-helix-loop-helix (bHLH) PAS transcription factors
that heterodimerize and transactivate the core clock compo-
nents such as Period (Per1, 2, 3), Cryptochrome (Cry1 andYagita et al. 90
Cry2) and Rev-Erbα [7, 12, 14]. PER and CRY proteins thus
suppress the activity of the CLOCK/BMAL1, whereas
REV-ERBα suppresses Bmal1 gene expression.
It has been thought that speed at which negative factors
such as mPERs and mCRYs accumulate in the cellular
nuclei control the period-length of circadian clock oscillator.
This nuclear accumulation of those proteins is affected by
their gene expression levels and nuclear translocation effi-
ciency, and the mPER2 and mCRY1 shuttle between nucle-
us and cytoplasm we previously reported may also con-
tribute to the nuclear accumulation process [18]. Among
the various steps of the circadian molecular oscillator, the
phosphorylation of clock proteins are believed to be im-
portant for the regulation of period-length. In this study,
we performed a screening analysis using a kinase inhibitor
library containing 84 compounds, focusing on the period-
length of the mammalian cellular circadian clock.
II. Materials and Methods
Cell culture and cell line establishment
Rat-1 fibroblast (HSRRB, Osaka, Japan) and C6 cells
were cultured in DMEM with 10% FBS and penicillin-
streptomycin. When cells were analyzed in our high-
throughput real time monitor system, the medium was
changed to HEPES-buffered phenol-red free DMEM, 24 hr
after transfection.
Real-time circadian rhythm monitoring
The mechanics of the bioluminescence detection
system used to analyze the circadian rhythm have been
described in previous reports [6]. Rat-1 or C6 cells were
cultured in 10% FBS and penicillin-streptomycin contain-
ing medium. Cells were plated in 35 mm dishes (2×105
cells/dish), the medium was changed to luciferine (0.2 mM)
and HEPES (15 mM) containing DMEM without phenol-
red. Cells were synchronized by treatment with 100 nM
dexamethasone and set on the turntable of our real-time
monitoring system.
Kinase inhibitor screening assay
For screening assay, we used a kinase inhibitor library
purchased from BIOMOL containing 84 compounds. These
kinase inhibitors were resolved in DMSO as 10 mM concen-
tration. For 24-well base screening using C6 cells, cells were
cultured in DMEM with 10% FBS for two days before
dexamethasone (Dex) treatment for synchronization. After
medium change to luciferin containing recording medium
as described above, cells were synchronized by 100 nM
Dex. Just after synchronization (within 10 min), the cells
were treated with the kinase inhibitors (see Fig. 1). The final
concentration of all inhibitors was 30 μM. All inhibitors
were applied to three wells for each compound. Circadian
clock oscillation was analyzed by 24-well based real-time
monitoring machines [6]. For detailed studies of the candi-
date kinase inhibitors after the screening, we also used
compounds purchased from Sigma and Calbiochem.
III. Results
Previous studies revealed that post-translational modi-
fication PER2 protein by phosphorylation is closely related
with period-length (tau) in mice and human [16, 17]. These
studies suggest that the phosphorylation of PER2 by CKIεδ
is the key step of the regulation of protein stability, and then
contributes the period-length control of clock oscillation.
These findings made us hypothesize that the phosphoryla-
tion step of clock components may control the circadian
period-length in mammals. In addition to the control of
mPER stability, recent reports revealed that F-box protein
FBXL3 was essential for mCRY ubiquitination, and that the
dysfunction of FBXL3 resulted in the severe period-length
change of circadian rhythm [1, 5, 15]. In general, F-box
proteins target the phosphorylation of substrates to start
poly-ubiquitination. The expression of FBXL3 level is con-
stitutive in all tissues examined. Moreover, we recently
reported that only faint changes of circadian period-length
Fig. 1. Experimental design of the screening. (A) Experimental
design of screening examining the effect of kinase inhibitors on the
circadian period-length in C6 and rat-1 cells. Before the dexa-
methasone synchronization of cellular circadian clock, cells
were precultured for two days. Just after Dex stimulation, kinase
inhibitors were applied to the cells. For this screening, all kinase
inhibitors were applied at a final concentration of with 30 μM. At
synchronization, the cells were confluent. (B) Control observation
of mPer2:luc stably transfected C6 cell line using our 24-well based
high-throughput real-time bioluminescence monitoring system.
Bioluminescence oscillation from all wells showed almost the same
phase and period-length.Effect of Kinase Inhibitors on Circadian Clock 91
were observed during the constitutive over-expression of
mCRY1 in rat-1 cells [20]. A recent in vivo study using
mCry1 in constitutively over-expressed transgenic mice
supports this result [11]. These findings suggest that the
control of phosphorylation in clock proteins can be the key
process to maintain the stable period-length of the mamma-
lian circadian clock. To address this hypothesis, we next
planned a screening analysis using a kinase inhibitor library
focusing on the period length control of the circadian clock.
Then we performed screening analysis using kinase in-
hibitor library including 84 compounds to investigate their
effect on period length signals (Fig. 1A). For the first screen-
ing, C6 glioma cells were used, since this cell line has been
frequently used to investigate the various signaling path-
ways in the neuroscience field in addition to exhibiting clear
circadian oscillation [3].
Before the screening, to evaluate the reproducibility of
bioluminescence rhythms, mPer2:luc reporter integrated C6
glioma cell lines were tested using the our 24-well plate
based high-throughput real-time monitor system. After syn-
chronization by dexamethasone treatment, the biolumines-
cence rhythms detected from each well showed almost the
same period lengths and phases (Fig. 1B).
We made a set of certain criteria to select candidate
inhibitors focused on period-length change: 1) changed
period-length, 2) arrhythmic, 3) unchanged period-length
(see Fig. S1, S2 and S3, respectively). Among the criteria
we chose only inhibitors showing period-length change,
since inhibitors showing arrhythmic phenotype in clock
oscillation must be appearing through a mixed effect,
such as toxic effect, although these may also contain some
important candidate for circadian clock regulation.
Through the screening assay, we could obtain seven
inhibitors showing apparent period-length change: IC261
(CKIε,δ inhibitor), DRB (5,6-dichloro-1-β-D-ribofuranosyl-
benzimidazole; CKII inhibitor), LY294002 (PI3K inhibitor),
SP600125 (JNK inhibitor), BML-297 (Akt inhibitor),
SB203580 and SB202190 (p38 MAPK inhibitors) (Fig. 1).
Fig. 2. Inhibitors against CKIεδ, CKII, PI3-K amd JNK dose-
dependently extend the period-length of mPer2 promoter driven
molecular oscillation in rat-1 cells. (A) Kinase inhibitor screening
assay revealed that the inhibitors against CKIεδ (IC261), CKII
(DMAT), PI3-K (LY294002) and JNK (SP600125) dose-depend-
ently extend the period-length of mPer2 promoter driven molecular
oscillation in rat-1 cells. Blue dots represent the DMSO treatment
as their control. Yellow and red dots represent 15 μM and 40 μM
concentrations of each inhibitor in mPer2:luc single stable trans-
fected rat-1 cells. Two samples were analyzed in each concentra-
tion. (B) Quantitative data of period-length in each kinase inhibitor
treatment. The numbers 15 and 40 after each inhibitor indicate their
final concentration. The numbers 1.5 and 4 after DMSO indicate
the amount of DMSO (1.5 μl and 4 μl, respectively) applied in the 2
ml culture medium.
Fig. 3. Possible model to explain the circadian period-length regula-
tion. Various kinases contribute to control period-length via the
various target components comprising the circadian feedback loop.
The activity fluctuation of these kinases may be correlated with
each other to express a self-sustaining robust circadian oscillation
with stable period-length.Yagita et al. 92
Among them, although p38 MAPK inhibitors showed pro-
longed period length, the bioluminescence intensity after
treatment by these compounds were severely decreased.
Also the effect of Akt inhibitor on the cellular circadian
period-length seemed to be weak. Thus, for detailed
analysis, we here chose the IC261, DRB, LY294002 and
SP600125 inhibitors investigate the regulation mechanisms
of circadian period-length in mammalian cells.
Next, to avoid the possibility that the effects of these
kinase inhibitors were C6 cell specific phenomena, we
investigated the effect of these compounds also using rat-1
fibroblast cells. The treatment of these kinase inhibitors
resulted in the longer period length of mPer2:luc driven bio-
luminescence oscillation in rat-1 cells dose dependently
(Fig. 2A and B). In these confirmation experiments, we used
DMAT  (2-dimethylamino-4,5,6,7-tetrabromo-benzimidazole)
instead of DRB, since DMAT is a specific CK2 inhibitor
and DRB is known to affect RNA polymelase II activity as
well [13]. Using Bmal1:luc reporter stably transfected cells,
we confirmed similar changes in their circadian period
lengths (data not shown). These results suggest that various
kinase and intracellular signaling pathways may contribute
to maintaining the stable period length of the mammalian
circadian clock.
IV. Discussion
Here we suggested the importance of protein phospho-
rylation by various kinases through various regulation path-
ways to maintain the period-length of mammalian circadian
clock. In this study, we performed a screening assay to
search the candidate kinases contributing to circadian
period-length control, and we could detect six kinases as
candidates. For long time, it has been believed that the
TTFL generates the circadian rhythm, and this model is
based on the “cyclic accumulation of clock gene products”.
In other words, the accumulation levels of core clock com-
ponents would reflect the time-of-day [10]. However, recent
studies including our works suggest that constitutive high-
level accumulation of core clock component such as mPer1,
mPer2 and mCry1 do not stop the oscillation in mammalian
circadian clock [2, 9, 11, 19, 20]. These results strongly
suggest that additional unknown mechanisms must reside in
the mammalian circadian clock system.
In this study, we revealed that the various chemical
compounds known as inhibitors for various kinases change
the circadian period-length in mammalian cells. Among the
targets of these inhibitors, the function of CKIεδ is well in-
vestigated in several studies. CKIεδ phosphorylates mPER
proteins and control their stability. A recent study reported
that CKII phosphorylates mPER2 protein and regulates its
stability [8]. This result is also compatible with our data of
this study. Gathering all observation in this study, we pro-
pose a possible model of mammalian circadian clock system
(Fig. 3). This model suggests two mechanistic insights of the
mammalian circadian clock: 1) CKIεδ and CKII collabora-
tively regulate the period-length through controlling the sta-
tus of mPER2 protein; and 2) multiple pathways control the
period-length via multiple clock components in the circadian
clock oscillator. Our findings may provide multiple possible
therapeutic targets to control circadian rhythm disorder.
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